RxDoctor Payments Data

Peter Rubin, MD

Gastroenterology · New York, NYNPI 1164467197

Payments from drug & device makers

$15,183in general payments, 2019–2025

Across 739 payments — averaging $20.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • QOL Medical, LLC$2K
  • Bristol Myers Squibb$1K
  • Johnson & Johnson$846
  • plus $4K from 31 others

What the payments were for

  • Consulting fees$260%
  • Food & beverage$15,02099%
  • Education$1371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$15,183 in reported general payments places this provider in the 80th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$230,023
Medicare patients
446
Services billed
2,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab20$135,777
Humira PenAdalimumab12$79,221
EliquisApixaban46$49,760
XifaxanRifaximin18$40,841
JardianceEmpagliflozin27$30,513
PentasaMesalamine14$21,822
ClenpiqSod Picosulf/Mag Ox/Citric Ac79$13,530
Mesalamine14$9,956
LinzessLinaclotide16$8,530
Repatha SureclickEvolocumab11$7,978
Janumet XrSitagliptin Phos/Metformin Hcl12$6,919
Mesalamine ErMesalamine15$4,840
CholestyramineCholestyramine (With Sugar)26$4,342
Dexlansoprazole DrDexlansoprazole24$3,870
Codeine Sulfate21$2,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$657$49,76046 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$2,305$40,84118 claims
Boehringer IngelheimJardiance$169$30,51327 claims
Ferring Pharmaceuticals Inc.Clenpiq$275$13,53079 claims
AbbVieLinzess, Synthroid$3,503$9,62535 claims
MerckJanumet Xr$151$6,91912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →